Valbiotis SA (ALVAL) AI Stock Analysis

Valbiotis SA

(Paris:ALVAL)

Select Model

Rating:39Underperform

Price Target:EUR 0.59▼(-5.72% Downside)

Action:reiterated

Date:10/15/26

Severe financial weakness is the primary drag, driven by ongoing losses, cash burn, and declining equity. Bearish technical trends and an unsupported negative P/E further weigh on the stock, although oversold momentum indicators and revenue growth provide limited offsetting positives.

Positive Factors

Revenue reboundThe reported 183.5% revenue-growth figure indicates a substantial rebound in commercial activity. If converted into repeat product or formulation sales, it could improve operating leverage and support market development, although the pack also describes revenue as volatile.

Negative Factors

Persistent lossesLarge recurring losses relative to revenue show that the current business has not yet reached profitable scale. Deeply negative operating and net margins can constrain reinvestment, increase dependence on financing, and make earnings improvement reliant on stronger commercialization.

Valbiotis SA (ALVAL) vs. iShares MSCI France ETF (EWQ)

Market Cap: EUR 22.31M
Dividend Yield: ―
Average Volume (3M): 109.47K
Price to Earnings (P/E): -2.1
Beta (1Y): -0.15
Revenue Growth: 183.47%
EPS Growth: 57.15%
Country: France
Employees: 50
Sector: Consumer Defensive
Sector Strength: 62
Industry: Biotechnology

Valbiotis SA Business Overview & Revenue Model

Company Description

Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases...

How the Company Makes Money

Valbiotis makes money primarily by commercializing its nutrition-health products and/or the underlying ingredients/formulations it develops, generating revenue from product sales (direct-to-consumer and/or through distribution channels such as pharma...

Valbiotis SA Financial Statement Overview

Summary

Revenue growth is strong, but persistent net losses, deeply negative margins, negative operating and free cash flow, rising leverage, and substantial equity erosion indicate severe financial risk.

Income Statement

25Negative

Balance Sheet

55Neutral

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	905.00K	905.00K	175.00K	4.73M	785.00K	298.00K
Gross Profit	-1.17M	-1.17M	-2.44M	2.69M	767.00K	282.00K
EBITDA	-9.15M	-9.32M	-9.17M	-6.41M	-11.13M	-9.14M
Net Income	-9.42M	-9.42M	-10.03M	-7.37M	-12.31M	-8.68M
Balance Sheet
Total Assets	14.39M	14.39M	19.61M	33.31M	27.17M	28.48M
Cash, Cash Equivalents and Short-Term Investments	8.68M	8.68M	11.58M	25.02M	20.83M	21.82M
Total Debt	5.09M	5.09M	5.72M	6.88M	7.18M	7.59M
Total Liabilities	7.43M	7.43M	9.24M	13.71M	13.86M	14.25M
Stockholders Equity	6.96M	6.96M	10.37M	19.60M	13.31M	14.23M
Cash Flow
Free Cash Flow	-8.19M	-8.19M	-11.80M	-8.30M	-9.48M	-7.58M
Operating Cash Flow	-8.04M	-8.04M	-11.54M	-8.06M	-9.19M	-7.16M
Investing Cash Flow	-77.00K	-77.00K	-61.00K	-250.00K	-197.00K	-7,000
Financing Cash Flow	5.21M	5.21M	-1.84M	12.49M	8.40M	14.40M

Valbiotis SA Technical Analysis

Technical Analysis SentimentNeutral

Last Price0.63

Price Trends

50DMA0.69Negative

100DMA0.75Negative

200DMA0.87Negative

Market Momentum

MACD-0.02Negative

RSI51.91Neutral

STOCH82.17Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVAL, the sentiment is Neutral. The current price of 0.63 is above the 20-day moving average (MA) of 0.58, below the 50-day MA of 0.69, and below the 200-day MA of 0.87, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 51.91 is Neutral, neither overbought nor oversold. The STOCH value of 82.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:ALVAL.

Valbiotis SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

FR:ALVAL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
FR:ALPAT	60Neutral	EUR 4.04M	6.98	―	―	-40.95%	-39.70%
FR:IVA	46Neutral	EUR 760.35M	-6.00	-1625.48%	―	-99.64%	68.67%
FR:POXEL	46Neutral	EUR 8.87M	-0.43	33.88%	―	―	―
FR:GNFT	44Neutral	EUR 541.90M	-5.32	279.22%	―	27.70%	-162.89%
FR:ALGAE	43Neutral	EUR 46.73M	-4.49	-32.62%	―	3.22%	24.05%
FR:ALVAL	39Underperform	EUR 22.31M	-2.13	-87.66%	―	183.47%	57.15%

* Consumer Defensive Sector Average

Performance Comparison

FR:ALVAL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
FR:ALVAL	Valbiotis SA	0.63	0.03	4.84%
FR:GNFT	Genfit SA	10.86	7.27	202.17%
FR:IVA	Inventiva SA	3.18	-0.49	-13.47%
FR:POXEL	Poxel SA	0.17	-0.16	-49.85%
FR:ALGAE	Fermentalg SA	0.39	-0.10	-19.92%
FR:ALPAT	Plant Advanced Technologies SA	3.56	-4.96	-58.22%

Valbiotis SA Corporate Events

Valbiotis Delivers First Chinese Joint-Venture Order

Nov 2, 2026

Valbiotis is a French cardiometabolic-health company developing clinically tested natural products based on patented active substances. Its market focus includes prevention and support for conditions such as cholesterol imbalance, metabolic disorders...

Valbiotis Adds Amazon France as New Digital Channel for Cardiometabolic Health Products

Oct 26, 2026

Valbiotis is expanding its distribution strategy by launching all its ValbiotisPRO and ValbiotisPLUS natural cardiometabolic health ranges on Amazon France, complementing its existing pharmacy and direct online sales channels. By entering France&#821...

Valbiotis Wins Double “Best Pharma Product 2027” Award in Cardiometabolic Health

Oct 19, 2026

Valbiotis has received a double “Best Pharma Product 2027” award for its Valbiotis PRO® Cholesterol and Valbiotis PRO® Metabolic Health solutions, following tests conducted by independent consumers in real-life conditions. The d...

Valbiotis updates share capital and voting rights, reinforces ownership disclosure rules

Oct 12, 2026

Valbiotis SA has reported its monthly share capital and voting rights status as of 30 September 2026, with 35,538,234 shares outstanding and 36,201,630 exercisable voting rights on Euronext Growth Paris. The disclosure reinforces transparency for inv...

Valbiotis Study Clears Path for Launch of Liver Health Product

Sep 22, 2026

Valbiotis reported positive results from its randomized, placebo-controlled Cardio-Liver study in 71 overweight or obese volunteers with hepatic steatosis, showing Steadrive reduces liver fat and improves several metabolic parameters. These findings...

Valbiotis updates share capital and voting rights, reinforces governance transparency

Sep 7, 2026

Valbiotis SA has published its monthly regulatory update on the composition of its share capital and voting rights as of August 31, 2026, in line with Article 223-16 of the AMF’s General Regulation. The company reports 35,538,234 shares outstan...

Valbiotis Reports July 2026 Share Capital and Voting Rights

Aug 17, 2026

Valbiotis SA has reported its monthly share capital and voting rights position as of July 31, 2026, in line with French market regulation. The company’s share capital stands at 35,538,234 shares, corresponding to 36,250,779 theoretical voting r...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 15, 2026

Valbiotis SA AI Stock Analysis